SEREVENT DISKUS (salmeterol xinafoate inhalation powder) contains salmeterol xinafoate as the racemic form of the 1-hydroxy-2-naphthoic acid salt of salmeterol. The active component of the formulation is salmeterol base, a highly selective beta2-adrenergic bronchodilator.
SEREVENT DISKUS is indicated for the following:
Asthma: SEREVENT DISKUS is indicated for long-term, twice-daily (morning and evening) administration in the maintenance treatment of asthma and in the prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease, including patients with symptoms of nocturnal asthma, who require regular treatment with inhaled, short-acting beta2-agonists. It is not indicated for patients whose asthma can be managed by occasional use of inhaled, short-acting beta2-agonists.
SEREVENT DISKUS is also indicated for prevention of exercise-induced bronchospasm in patients 4 years of age and older.
SEREVENT DISKUS may be used alone or in combination with inhaled or systemic corticosteroid therapy.
Chronic Obstructive Pulmonary Disease: SEREVENT DISKUS is indicated for the long-term, twice-daily (morning and evening) administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
Published Studies Related to Serevent Diskus (Salmeterol Inhalation Powder)
Long-term treatment with fluticasone propionate/salmeterol via Diskus improves asthma control versus fluticasone propionate alone. [2011.03]
This 52-week study was designed to assess the safety and efficacy of fluticasone propionate/salmeterol combination (FSC) 250/50 micrograms versus fluticasone propionate (FP) 250 micrograms in subjects with persistent asthma symptomatic on open-label FP 100 micrograms.In addition, FSC 250/50 micrograms-treated subjects experienced fewer severe asthma exacerbations than subjects treated with FP 250 micrograms.
Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. [2010.11.15]
RATIONALE: For children with symptomatic asthma despite low to moderate doses of inhaled corticosteroids, evidence is still lacking whether to add a long-acting bronchodilator or to increase the dose of inhaled corticosteroids. OBJECTIVE: To evaluate whether salmeterol/fluticasone propionate (SFP), 50/100 mug twice a day, is noninferior regarding symptom control compared with fluticasone propionate (FP), 200 mug twice a day Diskus in children with symptomatic asthma... CONCLUSIONS: In our study the efficacy on symptom control and lung function of the combination of a long-acting bronchodilator with inhaled corticosteroid is equal to doubling the dose of the inhaled corticosteroid in children still symptomatic on a moderate dose of inhaled corticosteroid.
Effect of addition of salmeterol versus doubling the dose of fluticasone propionate on specific airway resistance in children with asthma. [2010.09]
Based primarily on extrapolation from adult studies, current pediatric asthma guidelines advise the addition of long-acting beta-agonists for children symptomatic on low/moderate-dose inhaled corticosteroids before increasing the corticosteroid dose... Addition of salmeterol provides greater improvement in sR(aw) than doubling the dose of FP in children with moderate/severe persistent asthma.
Childhood evaluation of salmeterol tolerance--a double-blind randomized controlled trial. [2010.03]
Long acting beta(2)-agonists (LABA) are widely used in children with asthma...
Fixed or adjustable maintenance-dose budesonide/formoterol compared with fixed maintenance-dose salmeterol/fluticasone propionate in asthma patients aged >or=16 years: post hoc analysis of a randomized, double-blind/open-label extension, parallel-group study. 
BACKGROUND AND OBJECTIVE: Inhaled corticosteroid (ICS)/long-acting beta(2)-agonist (LABA) combinations are the preferred maintenance therapy for adult asthma patients uncontrolled by ICS alone. Supporting data are largely from mixed populations of adolescents and adults, although ICS/LABA combinations are not approved for adolescents in all countries. This analysis evaluates overall asthma control in asthma patients aged >or=16 years receiving ICS/LABA combinations... CONCLUSIONS: This post hoc analysis supports the use of ICS/LABA combinations in adults aged >or=16 years.
Clinical Trials Related to Serevent Diskus (Salmeterol Inhalation Powder)
Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate [Completed]
This study may last up to 36-38 weeks. Patients will visit the clinic 11 times. A blood
sample will be taken at Visit 1 to look at subjects' genes. Breathing tests will be done
during the study. Study medicines and procedures will be provided at no cost. Patients will
be treated with VENTOLIN (8 wks), ATROVENT (8 wks), then ADVAIR or SEREVENT (16 wks). ADVAIR
and SEREVENT are FDA approved for the treatment of asthma in patients 4 years of age and
Repeat Dose Study of Fluticasone Propionate/Salmeterol Versus Fluticasone Propionate + Salmeterol In Asthmatics [Completed]
A new formulation of Fluticasone propionate/Salmeterol comparing a lower dose of fluticasone
propionate and salmeterol was compared with concurrent administration of fluticasone
propionate and salmeterol. Administration occurred over 14 days and tolerability, PK
(pharmacokinetic) and PD (pharmacodynamic) measurements were performed.
Chronic Obstructive Pulmanary Disease (COPD) Post-hospitalization Study [Not yet recruiting]
This trial is a randomized, double-blind, parallel-group, multicenter study to be conducted
in the United States. The purpose of the study is to evaluate the rate of exacerbations of
chronic obstructive pulmonary disease (COPD) following hospital discharge for an acute
exacerbation of COPD, in patients receiving either fluticasone propionate/salmeterol
combination product 250/50mcg BID or salmeterol 50mcg BID via DISKUS™ over 29 weeks. The
study population will include patients hospitalized for an acute exacerbation of COPD. The
target enrolment is 720 subjects at 80 study centers. The primary endpoint is the rate of
exacerbation requiring hospitalization that occur more than 21 days post-discharge,
emergency room visit or physician's office visit for an exacerbation of COPD requiring
treatment with oral corticosteroids or oral corticosteroids and antibiotics. The secondary
endpoint is the rate of COPD exacerbation requiring treatment with oral corticosteroids,
antibiotics, and/or hospitalization (alone and in combination). Related efficacy endpoints
include, time to first exacerbation of COPD requiring treatment with oral corticosteroids,
antibiotics, and/or hospitalization (alone and in combination), pre-dose AM FEV1, the
probability of premature withdrawal of subject from the study, and supplemental albuterol
use, change in biomarkers of inflammation, including, surfactant protein D (SP-D), clara
cell secretory protein 16 (CC-16) and high sensitivity C-reactive protein (hs-CRP). Health
outcome assessments include domain scores evaluation for fatigue, dyspnea, emotional
function and mastery, measured with the Chronic Respiratory Disease Questionnaire
self-administered standardized format (CRQ-SAS); and symptoms (congestion, cough, phlegm,
mucus, chest discomfort, shortness of breath and sleep disturbance), assessed by the
EXAcerbations of Chronic pulmonary disease Tool (EXACT). Albuterol will be supplied to
study subjects for use as-needed throughout the study. Safety will be assessed by
monitoring of adverse events.
Study to Investigate the Effect of Formoterol vs Salmeterol on Small Airways Physiological Parameters in COPD Patients [Recruiting]
This is a crossover Study to investigate the effect of Formoterol versus Salmeterol on small
airways physiological parameters in COPD patients.
How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment [Recruiting]
The purpose of the study is to find out how well a long-acting beta agonist like salmeterol
works in people with different forms of the same gene. Our hypothesis is that asthmatics
with the Arg/Arg genotype will have loss of bronchoprotection against exercise-induced
asthma with regular salmeterol treatment, as compared to asthmatics with the Gly/Gly
Page last updated: 2011-12-09